News and insights

Subscribe to our newsletter
Screens of the ӳý’s entire DOS (Diversity Oriented Synthesis) library of over 100,000 small molecules on the malaria parasite P. falciparum have identified compounds that act on a novel malaria target during all three stages of the disease.

After screening a library of over 100,000 small molecules, researchers from the ӳý of MIT and Harvard have identified compounds that act on a novel target in the malaria parasite, Plasmodium falciparum. resulted in the publication of a paper (available online September 7 inNature] and an open, data-rich resource for the malaria research community called the(MTRP).

The ExAC resource contains data on the exome sequences (protein-<br />coding portions of the genome) from 60,706 people from diverse<br /> ethnic backgrounds. <br /><i>Image by ӳý Communications/iStockphoto</i>

Based on the largest resource of its kind, members of the Exome Aggregation Consortium (ExAC) led by scientists at the ӳý of MIT and Harvard report scientific findings from data on the exome sequences (protein-coding portions of the genome) from 60,706 people from diverse ethnic backgrounds. Containing over 10 million DNA variants – many very rare and most identified for the first time – the ExAC dataset is a freely available, high-resolution catalog of human genetic variation that has already made a major impact on clinical research and diagnosis of rare genetic diseases.

ӳý researchers Naomi Habib, Yinqing Li, and colleagues have developed Div-Seq, a new approach for studying the brain at the single-cell level.

Naomi Habib and Yinqing Li, researchers from the labs of ӳý core institute members Aviv Regev and Feng Zhang, report on a new contribution to the single-cell analysis toolkit. Their method combines the sequencing of RNA from isolated nuclei (sNuc-Seq), and tagging of regenerating cells (Div-Seq), to enable the study of previously intractable and rare cell types in the brain.

Not all cancer mutations are drivers; Target Accelerator takes aim at identifying the ones most important to human disease

If you walked into a cancer clinic ten years ago as a newly diagnosed patient, you’d likely get “standard of care” treatment based on the location of the cancer in your body and its stage. Make that same visit today and your physician may instead begin with a close look at your tumor’s DNA.